Abstract
The study of One Million U.S. Radiation Workers and Veterans, the Million Person Study (MPS), examines the health consequences, both cancer and non-cancer, of exposure to ionizing radiation received gradually over time. Recently the MPS has focused on mortality patterns from neurological and behavioral conditions, e.g., Parkinson’s disease, Alzheimer’s disease, dementia, and motor neuron disease such as amyotrophic lateral sclerosis. A fuller picture of radiation-related late effects comes from studying both mortality and the occurrence (incidence) of conditions not leading to death. Accordingly, the MPS is identifying neurocognitive diagnoses from fee-for-service insurance claims from the Centers for Medicare and Medicaid Services (CMS), among Medicare beneficiaries beginning in 1999 (the earliest date claims data are available). Linkages to date have identified»540,000 workers with available health information. Such linkages provide individual information on important co-factor and confounding variables such as smoking, alcohol consumption, blood pressure, obesity, diabetes and many other health and demographic characteristics. The total person-level set of time-dependent variables, outcomes, organ-specific dose measures, co-factors, and demographics will be massive and much too large to be evaluated with standard software. Thus, development of specialized open-source software designed for large datasets (Colossus) is nearly complete. The wealth of information available from CMS claims data, coupled with individual dose reconstructions, will thus greatly enhance the quality and precision of health evaluations for this new field of low-dose radiation and neurocognitive effects.
Original language | English |
---|---|
Pages (from-to) | 847-861 |
Number of pages | 15 |
Journal | Radiation Research |
Volume | 202 |
Issue number | 6 |
DOIs | |
State | Published - Oct 28 2024 |
Funding
NCRP acknowledges the financial support of the MPS from NASA (cooperative agreements 80NSSC17M0016 and 80NSSC19M0161), U.S. DOE (grants # DE-AU0000042 and DE-AU0000046), U.S. Naval Sea Systems Command (Contract N00024-17-C-4322) and the CDC (grant 5NUE1EH001315). Additional support was received from an NIH/NCI Cancer Center Support Grant (P30 CA008748) awarded to Sloan-Kettering Institute for Cancer Research (LTD, MB, DB). We acknowledge Floriane Poignant for technical assistance and Cato Milder for assistance on the Mallinckrodt and Fernald dose statistics. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of their respective agencies, universities or organizations.